4//SEC Filing
Lee Yuchun 4
Accession 0001209191-23-005712
CIK 0000875320other
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 4:42 PM ET
Size
12.2 KB
Accession
0001209191-23-005712
Insider Transaction Report
Form 4
Lee Yuchun
Director
Transactions
- Exercise/Conversion
Common Stock
2023-01-27$72.14/sh+1,429$103,088→ 3,304 total - Sale
Common Stock
2023-01-27$321.31/sh−379$121,776→ 2,925 total - Sale
Common Stock
2023-01-27$322.20/sh−970$312,534→ 1,955 total - Sale
Common Stock
2023-01-27$323.33/sh−80$25,866→ 1,875 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-27−1,429→ 0 totalExercise: $72.14Exp: 2024-05-31→ Common Stock (1,429 underlying)
Footnotes (5)
- [F1]Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- [F2]Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F3]Open market sales reported on this line occurred at a weighted average price of $321.31 (range $320.62 to $321.59).
- [F4]Open market sales reported on this line occurred at a weighted average price of $322.20 (range $321.75 to $322.74).
- [F5]Fully vested.
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeother
Related Parties
1- filerCIK 0001334365
Filing Metadata
- Form type
- 4
- Filed
- Jan 30, 7:00 PM ET
- Accepted
- Jan 31, 4:42 PM ET
- Size
- 12.2 KB